The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA

Infection, Genetics and Evolution

Volumn 21, Issue , 2014, Pages 575-582

  Howden, Benjamin P ^a,b,c   Peleg, Anton Y ^c,d,e   Stinear, Timothy P ^b,c  

^a AUSTIN HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e ALFRED HOSPITAL   (Australia)

Author keywords

Evolution; HVISA; Staphylococcus aureus; Vancomycin resistance; VISA

Indexed keywords

VIRULENCE FACTOR;

ANTIBIOTIC RESISTANCE; BACTERIAL GENOME; GENETIC VARIABILITY; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; METABOLISM; MICROBIOLOGY; MOLECULAR EVOLUTION; PHENOTYPE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EVOLUTION, MOLECULAR; GENETIC VARIATION; GENOME, BACTERIAL; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; PHENOTYPE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANCE; VIRULENCE FACTORS;

EID: 84893717765     PISSN: 15671348     EISSN: 15677257     Source Type: Journal    
DOI: 10.1016/j.meegid.2013.03.047     Document Type: Article

References (77)

1. Akins R.L., Rybak M.J. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 2001, 45:454-459.
2. Bae I.G., Federspiel J.J., Miro J.M., Woods C.W., Park L., Rybak M.J., Rude T.H., Bradley S., Bukovski S., De La Maria C.G., Kanj S.S., Korman T.M., Marco F., Murdoch D.R., Plesiat P., Rodriguez-Creixems M., Reinbott P., Steed L., Tattevin P., Tripodi M.F., Newton K.L., Corey G.R., Fowler V.G. Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. J. Infect. Dis. 2009, 200:1355-1366.
3. Bagnoli F., Bertholet S., Grandi G. Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials. Front. Cell. Infect. Microbiol. 2012, 2:16.
4. Boyle-Vavra S., Berke S.K., Lee J.C., Daum R.S. Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob. Agents Chemother. 2000, 44:272-277.
5. Boyle-Vavra S., Challapalli M., Daum R.S. Resistance to autolysis in vancomycin-selected Staphylococcus aureus isolates precedes vancomycin-intermediate resistance. Antimicrob. Agents Chemother. 2003, 47:2036-2039.
6. Boyle-Vavra S., Jones M., Gourley B.L., Holmes M., Ruf R., Balsam A.R., Boulware D.R., Kline S., Jawahir S., Devries A., Peterson S.N., Daum R.S. Comparative genome sequencing of an isogenic pair of USA800 clinical methicillin-resistant Staphylococcus aureus isolates obtained before and after daptomycin treatment failure. Antimicrob. Agents Chemother. 2011, 55:2018-2025.
7. Cameron D.R., Howden B.P., Peleg A.Y. The interface between antibiotic resistance and virulence in Staphylococcus aureus and its impact upon clinical outcomes. Clin. Infect. Dis. 2011, 53:576-582.
8. Cameron D.R., Ward D.V., Kostoulias X., Howden B.P., Moellering R.C., Eliopoulos G.M., Peleg A.Y. Serine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureus. J. Infect. Dis. 2012, 205:1677-1687.
9. Chambers H.F. The changing epidemiology of Staphylococcus aureus?. Emerg. Infect. Dis. 2001, 7:178-182.
10. Charles P.G., Ward P.B., Johnson P.D., Howden B.P., Grayson M.L. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin. Infect. Dis. 2004, 38:448-451.
11. Cosgrove S.E., Carroll K.C., Perl T.M. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin. Infect. Dis. 2004, 39:539-545.
12. Cui L., Lian J.Q., Neoh H.M., Reyes E., Hiramatsu K. DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 2005, 49:3404-3413.
13. Cui L., Ma X., Sato K., Okuma K., Tenover F.C., Mamizuka E.M., Gemmell C.G., Kim M.N., Ploy M.C., El-Solh N., Ferraz V., Hiramatsu K. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J. Clin. Microbiol. 2003, 41:5-14.
14. Cui L., Murakami H., Kuwahara-Arai K., Hanaki H., Hiramatsu K. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob. Agents Chemother. 2000, 44:2276-2285.
15. Cui L., Neoh H.M., Shoji M., Hiramatsu K. Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 2009, 53:1231-1234.
16. de Lassence A., Hidri N., Timsit J.F., Joly-Guillou M.L., Thiery G., Boyer A., Lable P., Blivet A., Kalinowski H., Martin Y., Lajonchere J.P., Dreyfuss D. Control and outcome of a large outbreak of colonization and infection with glycopeptide-intermediate Staphylococcus aureus in an intensive care unit. Clin. Infect. Dis. 2006, 42:170-178.
17. Delaune A., Dubrac S., Blanchet C., Poupel O., Mader U., Hiron A., Leduc A., Fitting C., Nicolas P., Cavaillon J.M., Adib-Conquy M., Msadek T. The WalKR system controls major staphylococcal virulence genes and is involved in triggering the host inflammatory response. Infect. Immun. 2012, 80:3438-3453.
18. Dubrac S., Bisicchia P., Devine K.M., Msadek T. A matter of life and death: cell wall homeostasis and the WalKR (YycGF) essential signal transduction pathway. Mol. Microbiol. 2008, 70:1307-1322.
19. Fridkin S.K., Hageman J., McDougal L.K., Mohammed J., Jarvis W.R., Perl T.M., Tenover F.C. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin. Infect. Dis. 2003, 36:429-439.
20. Fukushima T., Furihata I., Emmins R., Daniel R.A., Hoch J.A., Szurmant H. A role for the essential YycG sensor histidine kinase in sensing cell division. Mol. Microbiol. 2011, 79:503-522.
21. Gao W., Cameron D.R., Davies J.K., Kostoulias X., Stepnell J., Tuck K.L., Yeaman M.R., Peleg A.Y., Stinear T.P., Howden B.P. The RpoB H481Y rifampicin resistance mutation and an active stringent response reduce virulence and increase resistance to innate immune responses in Staphylococcus aureus. J. Infect. Dis. 2013, 207:929-939.
22. Gao W., Chua K., Davies J.K., Newton H.J., Seemann T., Harrison P.F., Holmes N.E., Rhee H.W., Hong J.I., Hartland E.L., Stinear T.P., Howden B.P. Two novel point mutations in clinical Staphylococcus aureus reduce linezolid susceptibility and switch on the stringent response to promote persistent infection. PLoS Pathog. 2010, 6:e1000944.
23. Gardete S., Kim C., Hartmann B.M., Mwangi M., Roux C.M., Dunman P.M., Chambers H.F., Tomasz A. Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300. PLoS Pathog. 2012, 8:e1002505.
24. Hafer C., Lin Y., Kornblum J., Lowy F.D., Uhlemann A.C. Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 2012, 56:5845-5851.
25. Hanaki H., Kuwahara-Arai K., Boyle-Vavra S., Daum R.S., Labischinski H., Hiramatsu K. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J. Antimicrob. Chemother. 1998, 42:199-209.
26. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect. Dis. 2001, 1:147-155.
27. Hiramatsu K., Aritaka N., Hanaki H., Kawasaki S., Hosoda Y., Hori S., Fukuchi Y., Kobayashi I. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997, 350:1670-1673.
28. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., Tenover F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 1997, 40:135-136.
29. Horne K.C., Howden B.P., Grabsch E.A., Graham M., Ward P.B., Xie S., Mayall B.C., Johnson P.D., Grayson M.L. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. Antimicrob. Agents Chemother. 2009, 53:3447-3452.
30. Howden B.P., Davies J.K., Johnson P.D., Stinear T.P., Grayson M.L. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 2010, 23:99-139.
31. Howden B.P., Johnson P.D., Ward P.B., Stinear T.P., Davies J.K. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 2006, 50:3039-3047.
32. Howden B.P., McEvoy C.R., Allen D.L., Chua K., Gao W., Harrison P.F., Bell J., Coombs G., Bennett-Wood V., Porter J.L., Robins-Browne R., Davies J.K., Seemann T., Stinear T.P. Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR. PLoS Pathog. 2011, 7:e1002359.
33. Howden B.P., Smith D.J., Mansell A., Johnson P.D., Ward P.B., Stinear T.P., Davies J.K. Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia. BMC Microbiol. 2008, 8:39.
34. Howden B.P., Stinear T.P., Allen D.L., Johnson P.D., Ward P.B., Davies J.K. Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus. Antimicrob. Agents Chemother. 2008, 52:3755-3762.
35. Howden B.P., Ward P.B., Charles P.G., Korman T.M., Fuller A., du Cros P., Grabsch E.A., Roberts S.A., Robson J., Read K., Bak N., Hurley J., Johnson P.D., Morris A.J., Mayall B.C., Grayson M.L. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. 2004, 38:521-528.
36. Howe R.A., Monk A., Wootton M., Walsh T.R., Enright M.C. Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages. Emerg. Infect. Dis. 2004, 10:855-857.
37. Jansen A., Turck M., Szekat C., Nagel M., Clever I., Bierbaum G. Role of insertion elements and yycFG in the development of decreased susceptibility to vancomycin in Staphylococcus aureus. Int. J. Med. Microbiol. 2007, 297:205-215.
38. Kaatz G.W., Seo S.M., Dorman N.J., Lerner S.A. Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. J. Infect. Dis. 1990, 162:103-108.
39. Katayama Y., Ito T., Hiramatsu K. A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 2000, 44:1549-1555.
40. Katayama Y., Murakami-Kuroda H., Cui L., Hiramatsu K. Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem. Antimicrob. Agents Chemother. 2009, 53:3190-3196.
41. Kelley P.G., Gao W., Ward P.B., Howden B.P. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. J. Antimicrob. Chemother. 2011, 66:1057-1060.
42. Koehl J.L., Muthaiyan A., Jayaswal R.K., Ehlert K., Labischinski H., Wilkinson B.J. Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 2004, 48:3749-3757.
43. Lowy F.D. Staphylococcus aureus infections. N. Engl. J. Med. 1998, 339:520-532.
44. Lowy F.D. Antimicrobial resistance: the example of Staphylococcus aureus. J. Clin. Invest. 2003, 111:1265-1273.
45. Majcherczyk P.A., Barblan J.L., Moreillon P., Entenza J.M. Development of glycopeptide-intermediate resistance by Staphylococcus aureus leads to attenuated infectivity in a rat model of endocarditis. Microb. Pathog. 2008, 45:408-414.
46. Manquat G., Croize J., Stahl J.P., Meyran M., Hirtz P., Micoud M. Failure of teicoplanin treatment associated with an increase in MIC during therapy of Staphylococcus aureus septicaemia. J. Antimicrob. Chemother. 1992, 29:731-732.
47. Maor Y., Hagin M., Belausov N., Keller N., Ben-David D., Rahav G. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J. Infect. Dis. 2009, 199:619-624.
48. Marco F., De La Maria C.G., Armero Y., Amat E., Soy D., Moreno A., Del Rio A., Almela M., Mestres C.A., Gatell J.M., Jimenez de Anta M.T., Miro J.M. Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 2008, 52:2538-2543.
49. Matsuo M., Hishinuma T., Katayama Y., Cui L., Kapi M., Hiramatsu K. Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3. Antimicrob. Agents Chemother. 2011, 55:4188-4195.
50. McAleese F., Wu S.W., Sieradzki K., Dunman P., Murphy E., Projan S., Tomasz A. Overexpression of genes of the cell wall stimulon in clinical isolates of Staphylococcus aureus exhibiting vancomycin-intermediate- S. aureus-type resistance to vancomycin. J. Bacteriol. 2006, 188:1120-1133.
51. McCallum N., Karauzum H., Getzmann R., Bischoff M., Majcherczyk P., Berger-Bachi B., Landmann R. In vivo survival of teicoplanin-resistant Staphylococcus aureus and fitness cost of teicoplanin resistance. Antimicrob. Agents Chemother. 2006, 50:2352-2360.
52. Moise P.A., North D., Steenbergen J.N., Sakoulas G. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect. Dis. 2009, 9:617-624.
53. Musta A.C., Riederer K., Shemes S., Chase P., Jose J., Johnson L.B., Khatib R. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11years. J. Clin. Microbiol. 2009, 47:1640-1644.
54. Mwangi M.M., Wu S.W., Zhou Y., Sieradzki K., de Lencastre H., Richardson P., Bruce D., Rubin E., Myers E., Siggia E.D., Tomasz A. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc. Natl. Acad. Sci. USA 2007, 104:9451-9456.
55. Neoh H.M., Cui L., Yuzawa H., Takeuchi F., Matsuo M., Hiramatsu K. Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance. Antimicrob. Agents Chemother. 2008, 52:45-53.
56. Park C., Shin N.Y., Byun J.H., Shin H.H., Kwon E.Y., Choi S.M., Kim S.H., Kwon J.C., Park S.H., Choi J.H., Yoo J.H., Yoo J.I., Chung G.T., Lee D.G. Downregulation of RNAIII in vancomycin-intermediate Staphylococcus aureus strains regardless of the presence of agr mutation. J. Med. Microbiol. 2012, 61:345-352.
57. Passalacqua K.D., Satola S.W., Crispell E.K., Read T.D. A mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin. Antimicrob. Agents Chemother. 2012, 56:5212-5223.
58. Peleg A.Y., Monga D., Pillai S., Mylonakis E., Moellering R.C., Eliopoulos G.M. Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection. J. Infect. Dis. 2009, 199:532-536.
59. Pereira P.M., Filipe S.R., Tomasz A., Pinho M.G. Fluorescence ratio imaging microscopy shows decreased access of vancomycin to cell wall synthetic sites in vancomycin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 2007, 51:3627-3633.
60. Perichon B., Courvalin P. VanA-type vancomycin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 2009, 53:4580-4587.
61. Pfeltz R.F., Singh V.K., Schmidt J.L., Batten M.A., Baranyk C.S., Nadakavukaren M.J., Jayaswal R.K., Wilkinson B.J. Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds. Antimicrob. Agents Chemother. 2000, 44:294-303.
62. Pillai S.K., Wennersten C., Venkataraman L., Eliopoulos G.M., Moellering R.C., Karchmer A.W. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus. Clin. Infect. Dis. 2009, 49:1169-1174.
63. Rammelkamp C.H., Maxon T. Resistance of Staphylococcus aureus to the action of penicillin. Proc. Royal Soc. Exper. Biol. Med. 1942, 51:386-389.
64. Renzoni A., Andrey D.O., Jousselin A., Barras C., Monod A., Vaudaux P., Lew D., Kelley W.L. Whole genome sequencing and complete genetic analysis reveals novel pathways to glycopeptide resistance in Staphylococcus aureus. PLoS One 2011, 6:e21577.
65. Robert J., Bismuth R., Jarlier V. Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20year study in a large French teaching hospital, 1983-2002. J. Antimicrob. Chemother. 2006, 57:506-510.
66. Rybak M.J., Cha R., Cheung C.M., Meka V.G., Kaatz G.W. Clinical isolates of Staphylococcus aureus from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin. Diagn. Microbiol. Infect. Dis. 2005, 51:119-125.
67. Scherl A., Francois P., Charbonnier Y., Deshusses J.M., Koessler T., Huyghe A., Bento M., Stahl-Zeng J., Fischer A., Masselot A., Vaezzadeh A., Galle F., Renzoni A., Vaudaux P., Lew D., Zimmermann-Ivol C.G., Binz P.A., Sanchez J.C., Hochstrasser D.F., Schrenzel J. Exploring glycopeptide-resistance in Staphylococcus aureus: a combined proteomics and transcriptomics approach for the identification of resistance-related markers. BMC Genomics 2006, 7:296.
68. Shoji M., Cui L., Iizuka R., Komoto A., Neoh H.M., Watanabe Y., Hishinuma T., Hiramatsu K. WalK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus. Antimicrob. Agents Chemother. 2011, 55:3870-3881.
69. Sieradzki K., Tomasz A. Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus. J. Bacteriol. 2003, 185:7103-7110.
70. Smith T.L., Pearson M.L., Wilcox K.R., Cruz C., Lancaster M.V., Robinson-Dunn B., Tenover F.C., Zervos M.J., Band J.D., White E., Jarvis W.R. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-intermediate Staphylococcus aureus working group. N. Engl. J. Med. 1999, 340:493-501.
71. Tenover F.C., Moellering R.C. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin. Infect. Dis. 2007, 44:1208-1215.
72. Tenover F.C., Sinner S.W., Segal R.E., Huang V., Alexandre S.S., Mcgowan J.E., Weinstein M.P. Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy. Int. J. Antimicrob. Agents 2009, 33:564-568.
73. van Hal S.J., Jones M., Gosbell I.B., Paterson D.L. Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections. PLoS One 2011, 6:e21217.
74. van Hal S.J., Paterson D.L. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 2011, 55:405-410.
75. Watanabe Y., Cui L., Katayama Y., Kozue K., Hiramatsu K. Impact of rpoB mutations on reduced vancomycin susceptibility in Staphylococcus aureus. J. Clin. Microbiol. 2011, 49:2680-2684.
76. Wootton M., Howe R.A., Hillman R., Walsh T.R., Bennett P.M., Macgowan A.P. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J. Antimicrob. Chemother. 2001, 47:399-403.
77. Yamakawa J., Aminaka M., Okuzumi K., Kobayashi H., Katayama Y., Kondo S., Nakamura A., Oguri T., Hori S., Cui L., Ito T., Jin J., Kurosawa H., Kaneko K., Hiramatsu K. Heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) emerged before the clinical introduction of vancomycin in Japan: a retrospective study. J. Infect. Chemother. 2012, 18:406-409.